Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review.
about
The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia.Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, ChinaSeroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testingGeographic integration of hepatitis C virus: A global threat.A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users.The HCV Synthesis Project: scope, methodology, and preliminary results.A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.Advances in genetic studies of substance abuse in ChinaAccess to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting.Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.Can HCV be prevented among injection drug users?Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmissionPrevention of hepatitis C virus infection.Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral HepatitisHepatitis C Virus and Associated Risk Factors among Prison Inmates with History of Drug Injection in Isfahan, Iran.The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned.Limited uptake of hepatitis C treatment among injection drug usersOpioids and HIV/HCV infection.Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting.Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy.Theory versus practice, bacteriological efficiency versus personal habits: A bacteriological and user acceptability evaluation of filtering tools for people who inject drugs.Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users.Health trends among drug users attending needle exchange programmes in Switzerland (1994-2000).The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium.Multiple viral hepatitis in injection drug users and associated risk factors.[AIDS. New challenges for social and medical prevention].
P2860
Q24811537-F4606492-623A-4993-89F0-3EA4A5D0052BQ27486520-325E20F5-B5C0-4D63-B324-F79DDF08F97AQ28545237-502FF342-FAD5-4B79-B5FE-1B620511F799Q30395543-59ADA857-518D-4B47-B9C0-0E351DA44B84Q33256564-AA7B23B8-0615-41D2-AF6D-0F6DB591F61BQ33369233-0573A354-EA5E-43C4-9513-4294A842840BQ33483115-815AFC37-8CB6-44B8-900B-3453EE6D005AQ33744466-2A21048A-0286-40C0-9E9F-C285310E9021Q33802414-2670685B-D352-422E-9DA8-E2DB1D27A483Q34332039-E0F5140D-6F52-4016-949F-38F3BB4640C5Q34539238-FDE67D74-A6AB-429B-9B01-56D9B3D581A4Q34789013-56B75904-53EA-4F03-ACDC-0DE4EF71EA72Q35057878-BC545C0F-A524-436E-995A-C55ADEB888D2Q35751678-E0A85576-A5DF-4E4F-9734-9A7E97FF8F05Q35760264-04D623D1-4ACB-43E8-B128-D0F24D88FB77Q35764220-E3C9E8CF-3BC3-4F1E-9813-B6B8AF91E9A1Q36101899-DF32EBF8-3B22-47FB-843E-6D49347C6115Q36865669-1E2B5730-66CC-40EA-824D-ADFE3730B9F9Q37238205-3705FCFC-E2BF-466A-BBD2-E436DF5C55D5Q37607856-EB2CE1C1-26AE-4A84-8C6E-DAE70ECE11E3Q38471467-80E361AE-0B7F-4136-B483-9B7BD3D00C19Q39965299-ACDC48F9-75AC-479F-B1B9-2D870773112FQ40181018-25EDC434-48B4-4A34-8DB7-6EEA02BBF5CEQ42595031-5A70F595-BCDF-47F2-9137-F8A00664E59EQ42689877-64C31974-15E3-4B25-992D-295D21CBAB88Q43047212-E7A3924E-71DB-4E9E-9B0B-920561079B7AQ52290488-8F0604D0-DCA0-4749-9C7E-E6B9932BDDB0Q52889066-3DF94547-7B01-4EFB-8363-0CE48DF69549
P2860
Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@ast
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@en
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@nl
type
label
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@ast
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@en
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@nl
prefLabel
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@ast
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@en
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@nl
P2093
P2860
P1476
Seroprevalence of hepatitis C ...... ountries: a systematic review.
@en
P2093
Catharina Matheï
P van Damme
P2860
P304
P356
10.1046/J.1365-2893.2002.00339.X
P577
2002-05-01T00:00:00Z